Successful capital injection completed – before final outcome of ongoing study!

Lifecare has completed a private placement of NOK 45 million at a 26% discount to yesterday’s price, equivalent to NOK 2.5 and a theoretical price today of NOK 3.24. This has provided the company with the capital to proceed towards start of production.

Lifecare: Ticker: LIFE | Price: NOK 2,50 | Market Cap.: 295 MNOK | YTD price development: 47%

Lifecare is a Medtech company that develops a smart and revolutionary biosensor that, when inserted in the wrist for example, continuously monitors the glucose (sugar) level in the blood and displays it via e.g. a smart watch. This is badly needed by the more than 500 million patients with diabetes, but at the moment the most common method is to take blood samples several times a day. Lifecare’s sensor can also be used to detect other biomarkers, but currently the company’s focus is diabetes and to launch Sencell Glucose in 2024.

Capital “before” time

It was expected that the capital injection would only be implemented after the final results of the ongoing trial. However, Lifecare has managed to implement the capital route earlier and at a relatively small discount. This can be taken as an indication that the studies continue to yield positive results and that Lifecare can thus continue the process towards final development and market launch of the glucose sensor in 2024.

The market price is below the theoretical price

The share price of Lifecare has today fallen from NOK 3.40 yesterday to the offer price of NOK 2.50. However, the share price “should” only fall to the theoretical price of 3.24, as a maximum of 21 million shares will be issued at the price of NOK 2.50, compared to the barely 100 million shares issued at present.

Repair issue

As the capital injection has been made at a discount, a so-called “repair issue” will be made – a subsequent issue for the remaining shareholders of up to 3 million shares, corresponding to approximately 3% of the currently outstanding shares. The issue will also be at NOK 2.50. However, it will only be carried out if the share price is above NOK 2.50 at that time.

Price development for Lifecare AS vs Kapital Partner Healthcare Index year to date


Selected cases

Would you like to receive one of our newsletters? Please fill the form below. (Newsletters are in danish)

  • Investment cases – Newsletters with current investment cases from the Nordic growth exchanges and the life science sector.
  • IPOs – Updates on new and ongoing IPOs in Scandinavia and their results. (Newsletter from
  • Nyheder – News from and about Kapital Partner, including insight into the capital markets and stock exchange listings as well as invitations to investor meetings and events.
  • Danish Biotech Weekly – Ugentlig opdatering med nyheder og kursudvikling for alle danske, børsnoterede selskaber uanset hvilket land eller børs de er noteret

*If you want information about our upcoming investment association with a focus on the Nordic growth exchanges, including the opportunity to invest, sign up for the newsletter. Nyheder.

Investor network:

Do you want to be part of Kapital Partner’s investor network, where you get access to investments in companies and issues, as well as invitations to investor-oriented events,
please fill out the form in here.

Del indlægget på sociale media eller på email.